ReviewHepatology international2015
Sofosbuvir for treatment of chronic hepatitis C.
Review in Hepatology international, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
14 citing papers in PubMed, 1 synthesis or guideline pooled it, 30 citations in OpenAlex.
- Pooled it
- Pharmacokinetic interaction between atorvastatin and fixed-dose combination of sofosbuvir/ledipasvir in healthy male Egyptian volunteers.European journal of clinical pharmacology · 2021Trial
- Identification of Potent Zika Virus NS5 RNA-Dependent RNA Polymerase Inhibitors Combining Virtual Screening and Biological Assays.International journal of molecular sciences · 2023Article
- Antiviral Evaluation of UV-4B and Interferon-Alpha Combination Regimens against Dengue Virus.Viruses · 2021Article
- Current Status of Direct Acting Antiviral Agents against Hepatitis C Virus Infection in Pakistan.Medicina (Kaunas, Lithuania) · 2018Review
- The ProTide Prodrug Technology: From the Concept to the Clinic.Journal of medicinal chemistry · 2018Review
- Vedroprevir in the management of hepatitis C virus infection.Expert opinion on investigational drugs · 2017Review
- Sofosbuvir/velpatasvir: a pangenotypic drug to simplify HCV therapy.Hepatology international · 2017Review
- Elbasvir/grazoprevir for treatment of chronic hepatitis C virus infection.Hepatology international · 2017Review
- Management of chronic Hepatitis C at a primary health clinic in the high-burden context of Karachi, Pakistan.PloS one · 2017Article
- Liver pathology of hepatitis C, beyond grading and staging of the disease.World journal of gastroenterology · 2016Review
- Sofosbuvir and ledipasvir for HIV/HCV co-infected patients.Expert opinion on pharmacotherapy · 2016Review
- Direct antiviral agent treatment of decompensated hepatitis C virus-induced liver cirrhosis.World journal of gastrointestinal pharmacology and therapeutics · 2015Article
- Isothiazolo[4,3-MedChemComm · 2015Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 3 institutions in 1 country.
Funding
Abstract
Chronic hepatitis C is a leading cause of liver-related morbidity and mortality worldwide. If untreated, chronic hepatitis C can progress to advanced liver fibrosis, cirrhosis, liver failure, hepatocellular carcinoma and death. Until recently, treatment of hepatitis C predominantly constituted an immunomodulatory agent, peg-interferon-alfa and ribavirin. In 2011, the first class of directly acting antiviral agents, HCV NS3/4A serine protease inhibitors, was added to peg-interferon-alfa and ribavirin with increased efficacy. In the past year, an NS5B inhibitor, sofosbuvir, has emerged as a potent agent with pangenotypic efficacy, resulting in the first interferon-free regimen for the treatment of hepatitis C. This review summarizes the data that resulted in regulatory approval of sofosbuvir and highlights the future of hepatitis C therapy with sofosbuvir as the backbone of a highly effective antiviral regimen.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.